ASCO 2010 Intro

News
Article

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting.

Advancing quality through innovation

 

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting.

 

GI cancer specialists

Richard M. Goldberg, MD, Lineberger Comprehensive Cancer Center and Peter C. Enzinger, MD, Dana-Farber Cancer Institute

Renal cell carcinoma experts

Andrew J. Armstrong, MD, MSc, Duke Comprehensive Cancer Center, and Robert J. Motzer, MD, MSKK

Hematologic malignancy authority

Samuel M. Silver, MD, PhD, University of Michigan

Our coverage will include the most clinically relevant educational seminars, on-site sessions, abstracts, and breaking news. Please stay tuned over the next several weeks for the best of this year’s exciting meeting.

 

Recent Videos
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Related Content
Data may support the strong oncologic outcomes of less invasive surgical options for patients with node-negative disease after neoadjuvant chemotherapy.

Less Intensive Surgical Staging Shows Noninferiority in Breast Cancer Trial

Andrea Eleazar, MHS
December 11th 2025
Article

Data may support the strong oncologic outcomes of less invasive surgical options for patients with node-negative disease after neoadjuvant chemotherapy.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma

Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma

Ariana Pelosci
December 11th 2025
Article

The FDA has given a PDUFA date of April 8, 2026, to the nivolumab/AVD regimen for stage III or IV classical Hodgkin lymphoma.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.

Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer

Russ Conroy
December 11th 2025
Article

Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.

The incidence and severity of AEs with eryaspase/chemotherapy was generally consistent with previous reports of chemotherapy alone in advanced PDAC.

Eryaspase Does Not Improve Efficacy vs Chemotherapy Alone in Advanced PDAC

Roman Fabbricatore
December 11th 2025
Article

The incidence and severity of AEs with eryaspase/chemotherapy was generally consistent with previous reports of chemotherapy alone in advanced PDAC.